Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 1/20 | 0.30 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.30 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.30 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4540777 | 0.78 | POLB (0.33) | — | |
| SCHEMBL1286666 | 0.54 | CYP1A2 (0.50) | — | |
| SCHEMBL19890993 | 0.53 | MEN1 (0.50) | — | |
| SCHEMBL11821659 | 0.53 | ALDH1A1 (0.45) | — | |
| SCHEMBL8009914 | 0.52 | LMNA (0.45) | — | |
| Acetic Acid SCHEMBL508727 | 0.51 | CYP1A2 (0.38) | — | |
| SCHEMBL21222317 | 0.51 | NPC1 (0.50) | — | |
| SCHEMBL9136458 | 0.50 | RAB9A (0.48) | — | |
| SCHEMBL957404 | 0.49 | — | — | |
| SCHEMBL31219219 | 0.49 | HDAC6 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9765071-B2 | Substituted imidazo ring systems and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2017-09-19 | — | — | US | disclosed |
| US-20160194322-A1 | SUBSTITUTED IMIDAZO RING SYSTEMS AND METHODS | 3M INNOVATIVE PROPERTIES CO (US) | 2016-07-07 | — | — | US | disclosed |
| US-9328110-B2 | Substituted imidazo ring systems and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2016-05-03 | — | — | US | disclosed |
| US-8778963-B2 | Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-07-15 | — | — | US | disclosed |
| US-20140194628-A1 | SUBSTITUTED IMIDAZO RING SYSTEMS AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-07-10 | — | — | US | disclosed |
| US-20070219196-A1 | AMIDE SUBSTITUTED IMIDAZOPYRIDINES, IMIDAZOQUINOLINES, AND IMIDAZONAPHTHYRIDINES | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2007-09-20 | — | — | US | disclosed |
| US-20070099901-A1 | Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-05-03 | — | — | US | disclosed |
| US-20070072893-A1 | Substituted imidazo ring systems and methods | 3M INNOVATIVE PROPERTIES COMPANY | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072893-A1 | Substituted imidazo ring systems and methods | IL2, IRF3, EIF2AK2 | GRIN2D 4144/4885GRIN3B 2093/4885GRIN1 2099/4885 |
| US-20160194322-A1 | SUBSTITUTED IMIDAZO RING SYSTEMS AND METHODS | IL2, IRF3, EIF2AK2 | GRIN2D 4086/4885GRIN3B 2050/4885GRIN1 2580/4885 |
| US-20070219196-A1 | AMIDE SUBSTITUTED IMIDAZOPYRIDINES, IMIDAZOQUINOLINES, AND IMIDAZONAPHTHYRIDINES | IL2, IL4, IFNG | GRIN2D 3244/4885GRIN3B 2174/4885GRIN1 2281/4885 |
| US-20140194628-A1 | SUBSTITUTED IMIDAZO RING SYSTEMS AND METHODS | IL2, IRF3, EIF2AK2 | GRIN2D 4086/4885GRIN3B 2050/4885GRIN1 2580/4885 |
| US-20070099901-A1 | Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines | IFNG, IRF3, IDO1 | GRIN2D 4416/4885GRIN3B 3114/4885GRIN1 3977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.